Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) -
Forecast and Market Analysis to 2022

Description: Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Summary

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

UCB is developing epratuzumab as a potential treatment for lupus. Epratuzumab was initially developed by Immunomedics and in May 2006 was licensed to UCB, with exclusive worldwide rights to develop and market epratuzumab for all autoimmune disease indications. Immunomedics has retained the rights to epratuzumab in oncology indications, for which UCB has been granted a buy-in option.

Scope

- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Epratuzumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Epratuzumab for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Epratuzumab performance
- Obtain sales forecast for Epratuzumab from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
4 Disease Management
4.1 Diagnosis Overview
4.1.1 SLE Diagnosis
Table 12: Product Profile - Epratuzumab
Table 13: Epratuzumab SWOT Analysis, 2013
Table 14: Global SLE Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 15: Global LN Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 16: Number of Physicians Surveyed by Country

1.2 List of Figures
Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
Figure 3: Overview of the Treatment Management of SLE
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022

Ordering: Order Online - http://www.researchandmarkets.com/reports/2706485/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2706485/
Office Code: SCD2FPUR

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number
Sort code
Swift code
IBAN number
Bank Address
833 130 83
98-53-30
ULSBIE2D
IE78ULSB98533083313083
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World